FDA approves new use for Avastin
SILVER SPRING, Md. — The Food and Drug Administration announced approval of a new use for Avastin (bevacizumab), to treat patients with persistent, recurrent or late-stage cervical cancer. The drug works by interfering with blood vessels that fuel the development of cancerous cells.
“Avastin is the first drug approved for patients with late-stage cervical cancer since the 2006 approval of topotecan with cisplatin,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is also the first biologic agent approved for patients with late-stage cervical cancer and was approved in less than four months under the FDA’s priority review program, demonstrating the agency’s commitment to making promising therapies available to patients faster.”
Avastin is marketed by Genentech, a member of the Roche Group.
Little Seashell prepares for holiday season with new collection
TORONTO — Little Seashell Cards announced the launch of its French and English holiday 2014 cards. The collection uses hand-applied glitter and crystal rhinestone to showcase the colors and details.
Each card, which measures 6 by 4.5-in., includes a white premium envelope and is encased in clear protective bags. The cards carry a suggested retail price of $4.75. The complete collection can be viewed at LittleSeashellCards.com.
Pragma announces relaunch of Moxatag
NEW YORK — Pragma Pharmaceuticals announced the relaunch of Moxatag (amoxicillin extended-release tablets), 775 mg. The company acquired Moxatag from Shionogi Inc. in March 2014 and has been working to make the product available in time for the 2014-15 cold-and-flu season.
“Amoxicillin is the gold standard in treating strep pharyngitis. Simplifying the dosing regimen is a no brainer. Greater convenience to help patient compliance is key to ensuring effective antibiotic therapy,” a Pragma spokesperson said.
Moxatag is indicated for the treatment of tonsillitis and/or pharyngitis secondary to streptococcus pyogenes (S. pyogenes) in adult and pediatric patients 12 years of age or older, the company said. Fera Pharmaceuticals will manage the sales and marketing of Moxatag for Pragma.